LifeVantage News

LifeVantage Spokesperson Donny Osmond Appears on Dr Phil Show

Press Release | 2/11/2012

Donny Osmond, the 2009 "Dancing with the Stars" champion, said he had discovered what he called his own "fountain of youth"--Protandim--during his appearance on the Dr. Phil show. Donny added that he has taken Protandim for two years at his doctor's recommendation and has experienced many health benefits and anti-aging results.

"This continues to be an exciting time for Protandim and LifeVantage," said LifeVantage President and CEO, Douglas C. Robinson. "There is an ever increasing number of Nrf2 studies in many of the most respected universities and institutions around the world. It is also gratifying to know that Protandim is of such interest that people have been typing 'Protandim' in Google searches more than any other word recently."

About Protandim, the Nrf2 Synergizer

Protandim(R) is a clinically demonstrated supplement that provides substantial benefits for healthy aging. Nrf2 is a protein messenger contained in every cell of the body. When activated, Nrf2 enters the cell nucleus and turns on hundreds of survival genes, defensive, stress responsive, cytoprotective genes that enable cells to survive in the face of several different kinds of stress, particularly oxidative stress. This patented Nrf2-activating therapy works in a very different way than conventional antioxidant supplements. Unlike vitamin or carotenoid-containing products that have proven to be largely ineffective in reducing oxidative stress caused by free radicals, Protandim is an indirect antioxidant therapy, which stimulates the body's production of its own powerful antioxidant enzymes and other stress-related gene products. Protandim works at the cellular level, triggering cells to naturally increase production of protective antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione synthase, while decreasing production of pro-inflammatory signals. A peer-reviewed human clinical study showed that after Protandim was taken for 30 consecutive days, important biochemical markers of aging were decreased by an average of 40%. The study also reported that these markers of aging were reduced in the subjects taking Protandim to the level of a typical 20 year old. Protandim is currently the subject of several scientific studies at universities and research facilities. The nature and stages of the studies vary. Under the Dietary Supplement Health and Education Act, Protandim is considered a "dietary supplement". Protandim is not intended for the prevention, diagnosis, treatment, mitigation or cure of any disease.

LifeVantage to Announce Quarterly Results on February 14

Press Release | 2/8/2012

Investors interested in participating in the live call can dial (877) 604-9665 from the U.S. International callers can dial (719) 325-4886. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, February 16, 2012, by dialing (877) 870-5176 from the U.S., or (858) 384-5517 from international locations, and entering confirmation code 2407254.

There also will be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events.cfm . The webcast will be archived for 30 days.

LifeVantage to Present at ICR XChange Conference

Press Release | 1/4/2012

The LifeVantage investor presentation is scheduled for Thursday, January 12, 2012, at 9:25 am Eastern Time. The presentation will be webcast live and archived on the Investor Info portion of the Company's website.

About ICR XChange

The ICR XChange is one of the largest and most unique investor conferences of the year, and is open to institutional portfolio managers and analysts, sell-side research analysts, investment bankers from sponsoring firms only, private equity professionals, select media and invited guests of ICR. The event is expected to feature presentations by nearly 180 public and private companies, as well as, a variety of discussion panels and keynote presentations. Last year's attendance exceeded 1,500 institutional, corporate and media attendees, and this January ICR is expecting even greater participation. CNBC is also expected to broadcast live at the event for the sixth consecutive year.

LifeVantage Announces New Peer Reviewed Study

Press Release | 11/11/2011

Protandim(R), a patented dietary supplement comprised of five highly synergistic natural ingredients, was shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates Protandim's(R) ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes," which include genes that encode antioxidant enzymes, as well as anti-inflammatory and anti-fibrotic proteins.

The study, titled "Oxidative Stress in Health and Disease: The Therapeutic Potential of Nrf2 Activation" by Brooks M. Hybertson, Bifeng Gao, Swapan K. Bose, and Joe M. McCord, is published in the scientific journal Molecular Aspects of Medicine and may be found at the following link: http://www.ncbi.nlm.nih.gov/pubmed/22020111 .

"This study examined gene expression using Affymetrix(R) GeneChips and the relationships among the regulated genes using Ingenuity Pathway Analysis(R) in cultured human cells treated with Protandim(R)," said Dr. McCord, Chief Science Officer of LifeVantage and senior author of the study.

Thousands of genes were affected by Protandim(R) treatment, including prototypical Nrf2-dependent genes such as heme oxygenase-1. Pathway Analysis was utilized to glean insights from the upregulated and downregulated genes, and it revealed that many of the genes affected by Nrf2 activation are relevant to Alzheimer's Disease, atherosclerosis, and colon carcinoma, among other conditions. For the majority of the genes associated with these conditions by pathway analysis, Nrf2 activation in cultured cells regulated the genes in directions that opposed the changes produced by the disease processes.

Further, the study described a bioassay that allows for direct comparisons of efficacy among Nrf2 activators applied to cultured cells. The agents examined included Protandim(R) and sulforaphane, the well-studied Nrf2 activator found in broccoli, and two pharmaceutical Nrf2-activating products currently in phase 3 human clinical trials. One of these, bardoxolone methyl from Reata Pharmaceuticals/Abbott Laboratories, is a promising candidate for the treatment of chronic kidney disease in type II diabetes patients, based on their reported Phase 2 and Phase 3 human clinical trials to date. The other pharmaceutical product, BG-12 (dimethyl fumarate) from Biogen Idec, is a promising candidate for the treatment of relapsing-remitting multiple sclerosis, based on their reported Phase 2 and Phase 3 human clinical trials results to date. Both pharma products recognize Nrf2 pathway activation as the basis of their physiological activity.

"The early successes of Nrf2 activation in the treatment of diseases as disparate as kidney failure and multiple sclerosis bodes well for the future usefulness of Nrf2 activation, whether managed by pharmaceutical products, dietary supplements such as Protandim(R), or by diet itself," said Dr. McCord.

"Protandim(R) was shown in an earlier human trial to increase antioxidant enzyme production and to eliminate the age-dependent increase in the most widely used marker of oxidative stress," stated Douglas C. Robinson, Chief Executive Officer of LifeVantage. "The current study, as well as other recent studies, have shown that Protandim(R) may provide benefits to the body that extend beyond its ability to decrease oxidative stress. Scientific publications such as these help raise the profile and expand the awareness of our product, and we look forward to continuing to help a growing number of people achieve their health and wellness goals."

LifeVantage Announces Record Fiscal Year

Press Release | 9/30/2011

For the fourth fiscal quarter ended June 30, 2011, the Company reported record net revenue of $15.0 million compared to $4.4 million for the same period in fiscal 2010, an increase of 241% from the prior year period. On a sequential basis, net revenue increased 50% from the $10.0 million reported for the third fiscal quarter ended March 31, 2011.

Gross profit for the fourth quarter of fiscal 2011 increased to $12.9 million compared to $3.7 million for the same period last year, delivering an improved gross margin of approximately 86%, compared to 83% for the same period last year.

Operating expenses for the fourth fiscal quarter of 2011 were $11.0 million compared to $4.0 million for the same period last year, and on a sequential basis increased 45% from $7.6 million in the third fiscal quarter of 2011. The increase on a sequential basis is due primarily to increased sales commissions which are a direct result of the Company's increased revenue. The increase also reflects greater investment in personnel and infrastructure to position the Company for future growth.

Operating income improved to $2.0 million for the fourth fiscal quarter of 2011 compared to a loss of $290 thousand in the same period last year. The fourth quarter of fiscal 2011 is the Company's fourth consecutive quarter of achieving operating income. Operating income margin improved to 13% in the fourth quarter compared to a negative margin in the same period last year.

Douglas C. Robinson, Chief Executive Officer of LifeVantage, stated, "We are extremely pleased to report a record year for LifeVantage, as our strong financial performance underscores the expanding awareness of Protandim® and the successful execution of our business model. On an annual basis, our revenue more than tripled compared to last year, and we increased our operating income in each quarter of fiscal 2011. We also made significant improvements to our balance sheet and ended the year in a very healthy financial position, which provides us the financial flexibility to make the appropriate strategic investments in fiscal 2012 to support our long-term growth opportunities."

Mr. Robinson continued, "As the scientific support of Protandim® grows and more people seek our products to improve their overall health and wellness, it is important for us to have the appropriate infrastructure to support the continued growth that we believe our business is capable of delivering. Looking toward fiscal 2012, we anticipate that our total net revenue will more than double compared to fiscal 2011 and our operating income will also increase by over 100%. To ensure that we are positioned to sustain rapid growth for years to come, we are committed to making the appropriate investments in our sales and marketing departments, research and development efforts, and within our corporate infrastructure. We are very focused on improving the efficiency of our organization and continuing to increase our operating income while we make these investments."

For the full year ended June 30, 2011, net revenue increased 238% to $38.9 million from $11.5 million in fiscal 2010. Gross profit improved to $33.0 million in fiscal 2011 compared to $9.6 million in fiscal 2010. Operating income increased to $3.7 million in fiscal 2011, compared to an operating loss of $7.3 million in fiscal 2010. Operating income margin improved to 9.5% for the year compared to a loss for the prior fiscal year.

The Company ended fiscal 2011 with a much stronger balance sheet than when the year began. Its cash balance improved to $6.4 million due to strong revenue growth and operating profits generated by the business. The Company generated $4.7 million of cash flow from operations for the full year fiscal 2011 compared to a cash use from operations of $4.5 million in fiscal 2010. During fiscal 2011, an aggregate face value of $5.6 million in debt was converted into shares of the Company's common stock, eliminating all convertible debt.

Due to the improvements made to its balance sheet in fiscal 2011 as well as the Company's outlook for strong operating cash flow in fiscal 2012, the Company recently announced a share repurchase program that authorizes it to utilize up to $5 million to purchase common stock over the course of the twelve months beginning October 1, 2011. Any such repurchases will be made only out of free cash flow from continuing operations and, on a quarterly basis, will not exceed 50% of free cash flow for such quarter.

LifeVantage At Accredited Members Conference

Press Release | 6/10/2011

LifeVantage Small Cap Equity Review

Press Release | 6/2/2011

"Lifevantage Corporation is in the midst of a turnaround story, and investors who take a closer look at the company may find an idea most everyone else is overlooking while searching for something a little sexier," says Brumley. The declining sales trend seen between 2006 and 2008 has been reversed, in spades. Fiscal 2010's $11.5 million in revenue is a record, even if it was paired with a record loss of $11 million. The numbers and the way Lifevantage's fiscal calendar falls, however, may obscure something very compelling that's just unfolded in the last three quarters... the company has swung to a profit, and just posted its best quarterly sales ever. It managed to turn $10.0 million in revenue last quarter into a profit of $792,000. Brumley adds "Just to put it into perspective, this supplement distributor generated $7.46 million in revenue for the prior quarter (a record at the time), and generated $6.4 million in sales for the quarter before that (also a record at the time). The bottom line has been reliable too, with an operating per-share profit of $0.01 three quarters ago, what would have been about $0.01 worth of per-share profit two quarters ago (a big accounting benefit boosted the total), and it posted earnings of about $0.01 per share for the most recently-completed quarter." Unlike so many other pill and supplement makers/distributors, Lifevantage has something unique, effective, and patented - Protandim. This supplement improves a user's innate antioxidant protection, and the claim has been verified - repeatedly - in clinical studies. As such, the organization clearly has something that some corporations never find, which is a marketable product and a business model that works.

LifeVantage Announces New President

Press Release | 3/16/2011

LifeVantage previously announced that the Board of Directors had opened a search for a new CEO to take over corporate responsibilities while current CEO David Brown would focus his efforts exclusively on continuing to expand the Company's network marketing channel. Mr. Brown will now serve as President & CEO of the network marketing operations and will remain as a member of the Company's Board of Directors.

"We are pleased that Doug will be joining the Company as President and CEO," stated Garry M. Mauro, LifeVantage's Chairman of the Board of Directors. "He brings tremendous knowledge and expertise as a seasoned executive and having been a member of the Board he has extensive experience with the Company's business operations."

"Given the significant growth and momentum we have generated and the continued opportunity before us, I believe, as does the Board, that I can bring the most value to shareholders by focusing solely on continuing to grow revenue and expand the network marketing business," David Brown added. "Doug's expertise in management and financial operations and corporate governance are important assets as we seek to continue the rapid expansion and growth of our business."

Douglas Robinson most recently served as Chief Executive Officer of WorkWell Systems, a rapidly growing physical medicine and workers' compensation solutions company. He is a seasoned executive with extensive experience in the Healthcare industry, bringing over 20 years of relevant industry experience, including senior roles at UnitedHealth Group, Deloitte Consulting and PriceWaterhouseCoopers.

Mr. Robinson holds a B.A. degree in Marketing/Public Relations and Speech Communications from Gonzaga University, Spokane, Washington where he also continues to guest lecture on healthcare economics to the undergraduate and graduate schools.

LifeVantage Dubs Protandim BSCG Approved

Press Release | 3/3/2011

"Samples of Protandim® have been analyzed for anabolic agents and stimulants and no prohibited compounds were detected in the product," stated Oliver Catlin, of the BSCG in Los Angeles, CA. "As a result, we have issued a certification for Protandim® at this time. The BSCG seal lets customers know the product has been certified and does not contain dangerous banned substances."

"We are proud that Protandim® has been scrutinized and certified by the BSCG to ensure that consumers and athletes are able to take the product with confidence," stated David W. Brown, President & CEO of LifeVantage. "We are pleased to participate in a program which helps to differentiate between responsible supplement manufacturers, of which we strive to be, and those whose products may present unnecessary risks."

"According to the BSCG, athletes are held personally liable for any substances prohibited by the USADA, the IOC, the NCAA, and the NFL which may be present in their bloodstream, regardless of the substances' origins," stated Gene Tipps, Senior Vice President of Operations of LifeVantage. "For this reason, athletes must be extremely careful about what they put into their bodies. We have found that a substantial number of athletes feel supplements are a vital part of their training regimen and as such, we are proud to be able to provide a quality product to those in the sports arena, athletes as well as consumers."

According to their website, the BSCG was founded by professionals with years of experience in the field of anti-doping analytical work and the group addresses the concern that dangerous banned substances can be found in dietary supplements, even when these substances are not listed as ingredients. The BSCG assists responsible dietary supplement manufacturers by utilizing cutting edge anti-doping methodology to analyze and certify that a sample of their product was tested for a list of banned substances, and that no banned substances were found in that sample above certain detection limits. More information on the BSCG can be found on their website, www.bscg.org.

LifeVantage Press Release

Press Release | 2/3/2011

LifeVantage Searches For New CEO

Press Release | 2/2/2011

Highly-qualified candidates may request consideration in confidence, by contacting LifeVantage via phone (801) 432-9038 or email executivesearch@lifevantage.com, no later than Tuesday, February 15th, 2011.

"Given the significant growth and momentum we have generated and the continued opportunity before us, I believe, as does the Board, that I can bring more value to shareholders by focusing solely on continuing to grow revenue and expand the network marketing business," Brown said. Brown will continue to serve as corporate President and CEO until a successor is named and will continue to occupy a position on the Board.

LifeVantage CEO Refocuses On Marketing Channel

Press Release | 1/24/2011

LifeVantage recently announced that it anticipates reporting its highest net revenue to date of approximately $7.4 million for the three month period ended December 31, 2010, an increase of approximately $1.0 million or 15% over net revenue of $6.4 million reported in the previous three month period ended September 30, 2010, and an approximate $4.9 million or 196% increase in net revenue over the $2.5 million net revenue reported for the same quarter last year.

Along with recording net revenue of $7.4 million, the Company also anticipates operating income of at least $500,000 in the second fiscal quarter 2011. Operating income of $500,000 would generate nearly a 7% operating profit margin, compared to an operating loss of $2.7M for the same quarter last year.

"We are pleased to announce that we are exceeding our previous guidance and anticipate reporting our highest quarterly net revenue to date," stated Brown. "These results reflect the continued growth we have seen from both the U.S. and Japanese markets. We'd like to thank all of our distributors, customers and employees responsible for these record results."

LifeVantage Press Release

Npros.com | 3/9/2010

Aspenwood Capital partner Steve Ossello said, "The Aspenwood partners have always been tremendous supporters of the company and its primary product - Protandim®. The science behind Protandim is incredible and given the recent quality additions to the board and the significant growth LifeVantage is experiencing, we're very excited about its potential."

LifeVantage CEO and President David Brown said, "We are extremely pleased with Aspenwood's continued support. The quality of both the institutional and individual investors that they have brought to our company is truly remarkable. We're confirming that this raise provides the company with the capital it needs to get through profitability."

LifeVantage Announces Board Expansion

Npros.com | 1/29/2010

The new additions broaden the range of expertise in corporate governance and oversight, management and financial operations, as well as business development. David W. Brown, President and CEO of LifeVantage stated: "We are delighted to welcome Mike, Kay and Doug to our Board of Directors. They bring tremendous knowledge and expertise within their respective fields. "We believe their experience will be an important asset as we seek to continue the rapid expansion and growth of our business." Mike Lu has been involved with investment analysis and portfolio management for over 20 years and is currently an independent investor in public markets and private equity. Mr. Lu managed the Janus Global Technology Fund from 1999 to 2006.

Kay Stout Manovich is a branding strategist, with more than 30 years of experience in comprehending, analyzing and improving brand communications and has worked behind such companies as: Coca-Cola, Kodak, Pizza Hut, Gerber, RadioShack, Neutrogena, Frito-Lay, Wacoal, Maybelline, Amore Pacific and Healthline.com.

Douglas Robinson is the CEO of WorkWell Systems, a medicine and workers' compensation solutions company, and a long time Healthcare industry executive. Mr Robinson has over 20+ years of experience having served with multiple companies and health administrations and has been vital in guiding some of the earliest total replacement consumer-driven healthcare efforts for several Fortune 500 employers.

Mexican government approves LifeVantage Protandim

Npros.com | 1/8/2010

After a pre-launch in Mexico, LifeVantage announced its entry into the international market in mid to late 2009.

"I'm excited Protandim is finally in Mexico - it has been a long time in coming. We are

enthusiastic about the potential health benefits to all in Mexico who use Protandim as well as to the opportunities for future research that the availability of the product in Mexico will provide. I believe there is not another product like Protandim in Mexico." said Daniel Hernandez-Saavedra, director or research for the Biochemical Research Center within the National Medical Center of Mexico. Mr Saavedra is also a LifeVantage Scientific Advisory Board member.

"We believe that the availability of Protandim in Mexico is a great opportunity for consumers seeking to improve their health. Furthermore, with the arrival of Protandim in Mexico, in addition to the availability of our TrueScience Anti-Aging Cream, our distributors are now fully empowered to enjoy the increased financial benefits of the LifeVantage business opportunity." said Francisco Varela, the national sales director of Mexico for LifeVantage.

LifeVantage Announces First Quarter Revenue

SunHerald.com | 10/17/2009

Total operating expenses in the first fiscal quarter of 2010 decreased by approximately 25% from total operating expenses of $6.1 million in the fourth fiscal quarter of 2009. This decline is primarily attributable to reductions of approximately 80% in total legal expenses. In the first fiscal quarter of 2010, legal expenses decreased by approximately $1 million and other operating expenses decreased by approximately $0.5 million. These decreases are directly attributable to the Company's efforts in expense reductions and greatly reduced activity in litigation in which the Company has been a party.

Article Link

LifeVantage Announces 4th Quarter 2009 Results

PR Newswire | 9/30/2009

The Company recorded net revenues of $4.1 million and a net loss of ($9.1) million, or ($0.23) per share, for its year ended June 30, 2009. For its year ended June 30, 2008, the Company recorded net revenues of $3.2 million and a net loss of ($2.1) million or ($0.09) per share.

During its fourth quarter fiscal year 2009, the Company recorded net revenue of $1.6 million, which represents an increase of approximately 150% from the net revenue of $0.6 million for the third quarter fiscal year 2009 and a net loss of ($5.3) million or ($0.11) per share. During its fourth quarter fiscal year 2008, the Company recorded net revenues of $0.8 million and a net loss of $(0.7) million, or $(0.03) per share.

Article Link

LifeVantage granted third patent for Protandim

Npros.com | 9/3/2009

Click below for the complete press release.

Article Link

LifeVantage Trims Operating Costs

Npros.com | 8/11/2009

LifeVantage Signs Agreement with Montel Williams

Press Release | 2/26/2009

Montel Williams commented, “My Living Well brand focuses on products and tools that are designed to promote a healthy lifestyle. I have been a fan of Protandim for several years and I feel the potential health benefits are numerous, making this an ideal fit with the other health and wellness products available via Living Well. Protandim significantly reduces oxidative stress, which is a key factor in many medical conditions and diseases, and I am excited to offer this outstanding product to health-conscious consumers.”

Article Link

LifeVantage Makes Record Setting Announcement

Press Release | 2/17/2009

David Brown, LifeVantage President and CEO, said, "We are extraordinarily fortunate to join forces with Jason, Tyler, Marcell and their team. Their one year revenue growth record is legendary in the industry and we believe could significantly impact LifeVantage's rapid expansion into the network marketing sales channel. Every network marketing company in the industry would love to have this team and the fact that they chose to join us is a testament to the strength of the science behind Protandim® and that they share our belief that this can become a powerful, global brand."

LifeVantage to Present at ROTH Capital Partners

MarketWatch | 2/11/2009

Article Link

LifeVantage PR Claims Protandim Results

Business Wire | 11/28/2008

Protandim®, a patented product developed by LifeVantage Corporation (OTCBB:LFVN), was proven by an earlier study to actually slow the progressive rate of aging. This new study confirms that Protandim’s® gene induction approach to antioxidant therapy provides much broader and more powerful benefits to the body than those provided by vitamins such as E and C, according to the Company.

Article Link

LifeVantage Shows Loss for Year

MarketWatch | 9/27/2008

For its fourth fiscal quarter 2008, the Company recorded net revenues of $0.8 million and a net loss of $(0.7) million, or $(0.03) per share. For its fourth fiscal quarter 2007, the Company reported net revenues of $0.8 million and a net loss of $(0.5) million, or $(0.02) per share.

Article Link

LiveVantage Announces Protandim Sales Increase

MarketWatch | 8/15/2008

SAN DIEGO, Aug 13, 2008 (BUSINESS WIRE) -- LifeVantage Corporation has announced it has increased distribution of Protandim(R) via a network of well-known regional brokers; the initiation of a direct sales program to healthcare professionals; and a partnership providing an entree into the fitness arena. According to Ben Seeman, LifeVantage's Vice President of Sales, "Upon joining the company approximately two months ago, my immediate focus was to accelerate product distribution within the United States. Leveraging my long standing relationships, we have created a strong network of brokers who have quickly brought on new retail accounts that are very excited about Protandim. Orders from these new accounts have already been received by the company." These new brokers include Contemporary Marketing, Inc.; Concept Sales and Associates; Colorado Natural Products; Gulf Coast Naturals; Fred Cordolla, LLC; and Steve Craner, LLC. LifeVantage is also seeing success in its new direct sales effort to doctors and healthcare professionals. Seeman commented, "The company's sales team is calling directly upon doctors, introducing them to a comprehensive new program that makes it easy for them to provide the tremendous benefits of Protandim to their patients. We have received a great response and new orders from this initiative. This effort aligns well with our new partnership with Chiropractic Buying Group, a company that provides information kiosks within chiropractic offices."

LifeVantage Appoints Richard Doutre Jones

Business Wire | 3/29/2008

David Brown, President and CEO of LifeVantage, commented, “Garry Mauro and Richard Doutre’ Jones are nationally recognized leaders in the business and civic sectors and we are honored to announce they have joined our Board of Directors. Mr. Mauro brings a legal, political and policy-making perspective to our Board, thanks to his impressive experience at the local, state and national level. He has an outstanding record in representing public and private sector interests, including serving a 16-year term as the Commissioner of the Texas General Land Office.”

Article Link

LifeVantage Expands Global Marketing Initiatives

Business Wire | 3/12/2008

David Brown, President and CEO of LifeVantage commented, “Jan and Peter bring proven track records and unparalleled expertise to our creative, marketing, and communications agendas. Peter’s acumen in brand building, marketing, and sales, together with Jan’s proven success in leading early stage companies to rapid growth and high visibility, will move the LifeVantage team to a whole new level. We are extremely excited to partner with both individuals in the continued growth, expansion and success of this company.”

Article Link

LifeVantage Announces 2Q 2007 Financials

Centre Daily Times | 2/22/2008

For the six month period ended December 31, 2007, the Company recorded net revenues of $1.6 million and a loss of $(0.7) million, or $(0.03) per share comparing to net revenues of $3.2 million and a loss of $(2.6) million, or $(0.12) per share for the six month period ended December 31, 2006.

Article Link

LiveVantage Announces Asia Market Expansion

Centre Daily Times | 2/22/2008

According to LifeVantage President and CEO David Brown, "NutraNomics has an excellent reputation as an organization that is known for its ability to quickly achieve successful product launches in Asia. NutraNomics has a proven track record in obtaining wide distribution with the leading companies including Miki Shoji, Japan's largest direct marketing company with over 500,000 distributors. In addition, the company has strong relationships with Mitsui Busan, Watakura, and Kanebo, through which NutraNomics distributes products in the Asian retail sector."

Article Link

Brown Named CEO of LifeVantage

Trading Markets | 1/16/2008

Nutrition Business Advisors was founded in 2003 to provide strategic consulting services, capital raising and full-service business development focused on the billion global nutrition industry. Prior to co-founding Nutrition Business Advisors, Brown was CEO of Metabolife International.

Greenwood Village, Colorado-based LifeVantage develops nutraceutical products, including Protandim, a dietary supplement.

Article Link